Andrea King to Middle Aged
This is a "connection" page, showing publications Andrea King has written about Middle Aged.
Connection Strength
0.686
-
Examining Electronic Nicotine Delivery System (ENDS) Cue Reactivity Using a Remote Platform: Cigarette and ENDS Desire in Dual Users. Nicotine Tob Res. 2025 Jul 22; 27(8):1332-1339.
Score: 0.059
-
Biomarkers of Nicotine and Tobacco Carcinogen Exposure in Socioeconomically Disadvantaged Black Adults Receiving a Brief Smoking Reduction Intervention. Cancer Epidemiol Biomarkers Prev. 2025 Jun 03; 34(6):982-989.
Score: 0.058
-
Implementation of a Telehealth Smoking Cessation Program in Primarily Socioeconomically Disadvantaged Black Patients: Courage to Quit Rolling-Virtual (CTQ-RV). Ann Behav Med. 2025 Jan 04; 59(1).
Score: 0.057
-
Effects of a brief motivational smoking intervention in non-treatment seeking disadvantaged Black smokers. J Consult Clin Psychol. 2021 Apr; 89(4):241-250.
Score: 0.043
-
Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. Alcohol Alcohol. 2019 Jan 09; 54(5):559-565.
Score: 0.037
-
Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenet Genomics. 2015 Jun; 25(6):305-12.
Score: 0.029
-
Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking. Alcohol Clin Exp Res. 2014 Oct; 38(10):2622-9.
Score: 0.028
-
Feasibility and effectiveness of a community-based smoking cessation intervention in a racially diverse, urban smoker cohort. Am J Public Health. 2014 Sep; 104 Suppl 4:S620-7.
Score: 0.028
-
Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial. Addiction. 2013 Oct; 108(10):1836-44.
Score: 0.026
-
Modifiable risk behaviors in patients with head and neck cancer. Cancer. 2013 Jul 01; 119(13):2419-26.
Score: 0.025
-
Project Exhale: preliminary evaluation of a tailored smoking cessation treatment for HIV-positive African American smokers. AIDS Patient Care STDS. 2013 Jan; 27(1):22-32.
Score: 0.025
-
Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry. 2013 May 01; 73(9):924-30.
Score: 0.024
-
Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012 Oct; 32(5):630-6.
Score: 0.024
-
Racial differences in eligibility and enrollment in a smoking cessation clinical trial. Health Psychol. 2011 Jan; 30(1):40-8.
Score: 0.021
-
Acute HPA axis response to naltrexone differs in female vs. male smokers. Psychoneuroendocrinology. 2010 May; 35(4):596-606.
Score: 0.020
-
A pilot community-based intensive smoking cessation intervention in African Americans: feasibility, acceptability and early outcome indicators. J Natl Med Assoc. 2008 Feb; 100(2):208-17.
Score: 0.018
-
Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res. 2006 Oct; 8(5):671-82.
Score: 0.016
-
Development of an alcohol biosensor non-wear algorithm: laboratory-based machine learning and field-based deployment. Sci Rep. 2025 Aug 25; 15(1):31154.
Score: 0.015
-
Client-related predictors of early treatment drop-out in a substance abuse clinic exclusively employing individual therapy. J Subst Abuse Treat. 2004 Apr; 26(3):189-95.
Score: 0.013
-
Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav. 2004 Jan; 77(1):29-37.
Score: 0.013
-
Alcohol-induced performance impairment in heavy episodic and light social drinkers. J Stud Alcohol. 2004 Jan; 65(1):27-36.
Score: 0.013
-
Stressful events, personality, and mood disturbance: gender differences in alcoholics and problem drinkers. Addict Behav. 2003 Jan-Feb; 28(1):171-87.
Score: 0.012
-
Role of naltrexone in initial smoking cessation: preliminary findings. Alcohol Clin Exp Res. 2002 Dec; 26(12):1942-4.
Score: 0.012
-
Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology. 2002 Jun; 26(6):778-88.
Score: 0.012
-
Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav. 2000 Jul; 66(3):563-72.
Score: 0.010
-
Differential fMRI BOLD responses in amygdala in intermittent explosive disorder as a function of past Alcohol Use Disorder. Psychiatry Res Neuroimaging. 2016 Nov 30; 257:5-10.
Score: 0.008
-
Substance use disorders: Relationship with intermittent explosive disorder and with aggression, anger, and impulsivity. J Psychiatr Res. 2016 10; 81:127-32.
Score: 0.008
-
The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl). 2013 May; 227(1):177-92.
Score: 0.006
-
Race and sex associations to weight concerns among urban African American and Caucasian smokers. Addict Behav. 2011 Jan-Feb; 36(1-2):14-7.
Score: 0.005
-
Effect of clinician advice and patient preparedness to quit on subsequent quit attempts in hospitalized smokers. J Hosp Med. 2010 Jan; 5(1):26-32.
Score: 0.005
-
Development of a culturally targeted smoking cessation intervention for African American smokers. J Community Health. 2009 Dec; 34(6):480-92.
Score: 0.005
-
Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts. Inflamm Bowel Dis. 2007 May; 13(5):573-9.
Score: 0.004
-
Cardiovascular responses to physical and psychological stress in female alcoholics with transitory hypertension after early abstinence. Alcohol Clin Exp Res. 2003 Sep; 27(9):1489-98.
Score: 0.003
-
Cortisol dysregulation and cognitive impairment in abstinent male alcoholics. Alcohol Clin Exp Res. 2002 Aug; 26(8):1198-204.
Score: 0.003